Hysbysiad gwybodaeth ymlaen llaw
Hysbysiad gwybodaeth ymlaen llaw yn unig yw hwn
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
Betsi Cadwaladr University Health Board
Headquarters, Ysbyty Gwynedd, Penrhosgarnedd
Bangor
LL57 2PW
UK
Person cyswllt: Victoria Allum
Ffôn: +44 2921501263
E-bost: vicky.allum@wales.nhs.uk
NUTS: UK
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://bcuhb.nhs.wales/
Cyfeiriad proffil y prynwr: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA88547
I.2) Caffael ar y cyd
Caiff y contract ei ddyfarnu gan gorff prynu canolog
I.3) Cyfathrebu
Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
Edoxaban Review Service
Cyfeirnod: BCU-MSP02-Edoxaban
II.1.2) Prif god CPV
85121100
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
The service is to review those prescribed edoxaban in primary care with a view to changing them to a more cost effective alternative.
II.1.5) Cyfanswm gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 322 860.00 GBP
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Na
II.2) Disgrifiad
II.2.3) Man cyflawni
Cod NUTS:
UKL11
UKL12
UKL13
UKL23
II.2.4) Disgrifiad o’r caffaeliad
Edoxaban Review Service is a service that requires a clinical review of all patients prescribed edoxaban for atrial fibrillation registered with GPs in BCUHB to assess if they are suitable for a more cost effective alternative and then change those that are.
Part 1 - Edoxaban Patient Review
Clinical review of the records of patients prescribed edoxaban.
Anyone not deemed suitable for the switch must be evidenced in the records, consider using the phrase
Edoxaban switch not clinically appropriate (no code) or,
Edoxaban contraindicated (SNOMED CT:2949391000000118) or,
Adverse reaction to edoxaban (SNOMED CT:1957181000006103).
Those deemed suitable for a switch proceed to a consultation with the patient or their representative. Consultations to switch edoxaban to generic apixaban or generic rivaroxaban can be done via telephone, virtually or face-to-face.
This must be documented in the notes, consider using the phrase
Edoxaban switch clinically appropriate (no code) or,
Edoxaban declined (SNOMED CT:1443911000000106)
Part 2 - Edoxaban Patient Review that results in a switch to generic apixaban or generic rivaroxaban
If clinically appropriate and the patient agrees to the switch to either generic rivaroxaban or generic apixaban; prescribe as indicated.
II.3) Dyddiad amcangyfrifedig ar gyfer cyhoeddi’r hysbysiad contract:
09/07/2026
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
Section VI: Gwybodaeth ategol
VI.3) Gwybodaeth ychwanegol
This is a Provider Selection Regime Wales (PSR Wales) intended approach notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award.
The decision makers will be the Heads of Pharmacy for primary care and community services and Medical Directors (East, Central and West) ratified by the Contract Management Group.
The intention is to award a contract using the most suitable provider process.
Publication of notice on 9th July, 14 days to respond by 22nd July. any queries and all responses to be sent to vicky.allum@wales.nhs.uk. Any responses received after this date will not be considered.
NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at http://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=166883.
(WA Ref:166883)
VI.5) Dyddiad anfon yr hysbysiad hwn
09/07/2026